HUE028067T2 - SAP variants and their application - Google Patents

SAP variants and their application Download PDF

Info

Publication number
HUE028067T2
HUE028067T2 HUE10790213A HUE10790213A HUE028067T2 HU E028067 T2 HUE028067 T2 HU E028067T2 HU E10790213 A HUE10790213 A HU E10790213A HU E10790213 A HUE10790213 A HU E10790213A HU E028067 T2 HUE028067 T2 HU E028067T2
Authority
HU
Hungary
Prior art keywords
sap
ahol ahol
variant
seq
amino acid
Prior art date
Application number
HUE10790213A
Other languages
English (en)
Hungarian (hu)
Inventor
W Scott Willett
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of HUE028067T2 publication Critical patent/HUE028067T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HUE10790213A 2009-06-17 2010-06-17 SAP variants and their application HUE028067T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26896109P 2009-06-17 2009-06-17

Publications (1)

Publication Number Publication Date
HUE028067T2 true HUE028067T2 (en) 2016-11-28

Family

ID=43354870

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10790213A HUE028067T2 (en) 2009-06-17 2010-06-17 SAP variants and their application
HUE15181052A HUE041034T2 (hu) 2009-06-17 2010-06-17 SAP-variánsok és alkalmazásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15181052A HUE041034T2 (hu) 2009-06-17 2010-06-17 SAP-variánsok és alkalmazásuk

Country Status (10)

Country Link
US (2) US8329659B2 (enExample)
EP (2) EP2987803B1 (enExample)
JP (2) JP5822826B2 (enExample)
AU (1) AU2010262847B2 (enExample)
CA (2) CA2765394C (enExample)
DK (2) DK2987803T3 (enExample)
ES (2) ES2552793T3 (enExample)
HU (2) HUE028067T2 (enExample)
PL (1) PL2987803T3 (enExample)
WO (1) WO2010148234A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
JP5980508B2 (ja) * 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
WO2010104959A1 (en) * 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2987803T3 (en) * 2009-06-17 2018-12-17 Promedior Inc SAP variants and their application
US20150087576A1 (en) * 2011-12-14 2015-03-26 The Texas A&M University System Compositions associated with and methods of managing neutrophil movement using serum amyloid p (sap)
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
ES2784234T3 (es) 2013-10-08 2020-09-23 Promedior Inc Métodos para el tratamiento de cánceres fibróticos
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
AU2016248317A1 (en) * 2015-04-15 2017-11-09 Promedior, Inc. Methods for treating myeloproliferative disorders
CN108114001B (zh) * 2017-12-23 2023-05-30 中国科学院海洋研究所 一种诱导海产双壳贝类产卵的诱导剂及其应用方法
EP3669885A1 (en) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Use of sap for the treatment of eurotiomycetes fungi infections
AU2021368272A1 (en) * 2020-11-02 2023-06-08 Attralus, Inc. Sap fc fusion proteins and methods of use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023A (en) * 1847-03-20 Stocking-loom
GB1562244A (en) 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
DE3853219T2 (de) 1987-11-20 1995-06-29 Kanegafuchi Chemical Ind Methode zur Entfernung von Serum-Amyloid-Protein.
US7070994B2 (en) 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5272258A (en) 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
US5092876A (en) 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
AU2158292A (en) 1991-05-31 1993-01-08 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5804446A (en) 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US6054121A (en) 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
WO1994027640A1 (en) 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
EP0915707B1 (en) 1996-01-25 2002-10-30 Profylakse ApS Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6365570B1 (en) 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
CN1307590A (zh) 1998-02-17 2001-08-08 米德列斯公司 用fc受体配基治疗和诊断巨噬细胞介导的疾病
ES2220257T1 (es) 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (en) 2000-03-30 2003-01-02 Brennen Medical Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7022476B2 (en) 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
NZ536555A (en) 2002-05-17 2007-03-30 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20050260213A1 (en) 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
CA2517037A1 (en) 2003-02-27 2004-09-10 Theravision Gmbh Method for reducing levels of c-reactive protein
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
US7378504B2 (en) 2004-06-03 2008-05-27 Medarex, Inc. Human monoclonal antibodies to Fc gamma receptor I (CD64)
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
BRPI0515589A (pt) 2004-09-02 2008-07-29 Genentech Inc polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
US7553653B2 (en) * 2004-09-17 2009-06-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
EP2505209A1 (en) 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
EP2185581B1 (en) * 2007-07-06 2015-09-02 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
JP5980508B2 (ja) 2009-03-11 2016-08-31 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
WO2010104959A1 (en) 2009-03-11 2010-09-16 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2987803T3 (en) * 2009-06-17 2018-12-17 Promedior Inc SAP variants and their application

Also Published As

Publication number Publication date
ES2708823T3 (es) 2019-04-11
DK2987803T3 (en) 2018-12-17
JP2012530714A (ja) 2012-12-06
AU2010262847A1 (en) 2012-01-19
HK1169997A1 (en) 2013-02-15
JP2015134824A (ja) 2015-07-27
PL2987803T3 (pl) 2019-04-30
JP6124943B2 (ja) 2017-05-10
AU2010262847B2 (en) 2016-06-02
US8329659B2 (en) 2012-12-11
ES2552793T3 (es) 2015-12-02
CA3083911C (en) 2022-11-29
HUE041034T2 (hu) 2019-05-28
CA3083911A1 (en) 2010-12-23
EP2987803B1 (en) 2018-08-29
CA2765394A1 (en) 2010-12-23
CA2765394C (en) 2020-08-18
EP2443144B1 (en) 2015-08-19
EP2443144A4 (en) 2012-11-28
HK1221478A1 (en) 2017-06-02
US9556246B2 (en) 2017-01-31
JP5822826B2 (ja) 2015-11-24
DK2443144T3 (en) 2015-11-23
US20100323970A1 (en) 2010-12-23
EP2443144A1 (en) 2012-04-25
US20130065838A1 (en) 2013-03-14
WO2010148234A1 (en) 2010-12-23
EP2987803A1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
CA3083911C (en) Sap variants and their use
JP2012530714A5 (enExample)
AU2011263786B2 (en) Tear lipocalin muteins binding IL-4 R alpha
KR20100017942A (ko) 독소 펩티드 치료제
JP2013515474A (ja) 組換え体ｈ因子ならびにそのバリアントおよびコンジュゲート
JP2018522547A (ja) Ｉｌ−３７バリアント
HK1221478B (en) Sap variants and their use
HK1169997B (en) Sap variants and their use
KR101293805B1 (ko) 돌연변이된 뉴블라스틴의 중합체 컨주게이트
HK1156051A (en) Polymer conjugates of mutated neublastin
HK1085663B (en) Mutated neublastin